• Phase 1 of the IMMUNICY-1 trial demonstrated encouraging data for CYAD-211, including a good safety profile and signs of clinical activity in patients with relapsed/refractory Multiple Myeloma (MM r/r ).
• In-depth data analysis is underway for the Phase 1b clinical trial, CYAD-101-002, following the FDA’s announcement of clinical suspension of the trial.
• The cash position was at 30.0 million euros (or 34.0 million dollars) as of December 31, 2021.
• A conference call and a webcast are scheduled for March 25, 2022 at 1:00 p.m. CET / 8:00 AM ET